EATRIS, the European infrastructure for translational medicine, obtained funding for a new flagship project for sustainability and personalised medicine: EATRIS-Plus. Alain van Gool (LabGK), Peter-Bram ‘t Hoen (CMBI) and Ariaan Siezen (IM) are co-PI’s and receive approximately 550 k€ from this 5M€ Horizon2020 infrastructure development grant.
The project aims to build further capabilities and deliver innovative scientific tools to support the long-term sustainability of EATRIS. A key output of the project will be the piloting and delivery of a multi-omic toolbox, that will include SOPs, guidelines for best practices, reference materials, quality parameters, analysis tools, criteria for establishing reference values, and will provide access to a repository of multi-omic data. Objectives that are in line with the ambitions of the Netherlands X-omics Initiative, coordinated by Van Gool.
EATRIS covers over 90 institutes across Europe, among which Radboudumc. It has shown strong proof of concept of the value and utility of its translational medicine services portfolio, with users including academia, SMEs, large pharma, biotech and research funding organisations. The overarching aim of EATRIS-Plus is to further support the long-term sustainability of EATRIS by delivering innovative scientific tools to the personalised medicine research community. EATRIS-Plus will help pooling and utilising the translational academic capacities of the infrastructure in omics technologies to enable researchers to better address the scientific and societal challenges of personalised medicine.
More information: link.
Related news items
A personal touch of Marlies Cornelissen31 October 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Marlies Cornelissen.read more
Collective cancer invasion forms an integrin-dependent radioresistant niche29 October 2019
Anna Häger and Peter Friedl, theme Cancer development and immune defense, identified a new niche of cancer cell survival and developed an integrin inhibition therapy to overcome resistance. They have published their results in JEM.read more
Algorithm to predict which cancer patients benefit from immunotherapy29 October 2019
Rik Lindeboom and Michiel Vermeulen, theme Cancer development and immune defense, have developed an algorithm that can predict which cancer patients are more likely to benefit from immunotherapy. This new technology’s potential is described in Nature Genetics.read more
X² Ambition Award for Sandra Heskamp28 October 2019
This award is intended for 'coming women’: young, ambitious women at a stage of their careers where they make important career choices. This prize is especially for women who show exemplary behaviour within the organization where they work, but also outside their organization.read more
A personal touch of Mariya Chernyavska24 October 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Mariya Chernyavska.read more